|Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma|
RJ Motzer, TE Hutson, MR Olsen, GR Hudes, JM Burke, WJ Edenfield, ...
Journal of clinical oncology 30 (12), 1371-1377, 2012
|Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug|
M Morgen, C Bloom, R Beyerinck, A Bello, W Song, K Wilkinson, ...
Pharmaceutical research 29 (2), 427-440, 2012
|Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma|
CH Barrios, D Hernandez‐Barajas, MP Brown, SH Lee, L Fein, JH Liu, ...
Cancer 118 (5), 1252-1259, 2012
|Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors|
X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang, J Shen, HE Vezina, ...
Annals of Oncology 28 (8), 2002-2008, 2017
|Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects|
DA Gajjar, A Bello, Z Ge, L Christopher, DM Grasela
Antimicrobial agents and chemotherapy 47 (7), 2256-2263, 2003
|Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections|
S Van Wart, L Phillips, EA Ludwig, R Russo, DA Gajjar, A Bello, ...
Antimicrobial agents and chemotherapy 48 (12), 4766-4777, 2004
|Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer|
GV Long, SS Tykodi, JG Schneider, C Garbe, G Gravis, M Rashford, ...
Annals of Oncology 29 (11), 2208-2213, 2018
|A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors|
CJ Sweeney, EG Chiorean, CF Verschraegen, FC Lee, S Jones, M Royce, ...
Journal of clinical oncology 28 (29), 4513, 2010
|Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.|
C Li, C Alvey, A Bello, KD Wilner, W Tan
Journal of Clinical Oncology 29 (15_suppl), e13065-e13065, 2011
|Clinical pharmacology considerations for the development of immune checkpoint inhibitors|
J Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M Gupta
The Journal of Clinical Pharmacology 57, S26-S42, 2017
|Effects of the des-F (6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats|
EM Kappel, M Shakibaei, A Bello, R Stahlmann
Antimicrobial agents and chemotherapy 46 (10), 3320-3322, 2002
|Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer|
Y Feng, X Wang, G Bajaj, S Agrawal, A Bello, B Lestini, FG Finckenstein, ...
Clinical Cancer Research 23 (18), 5394-5405, 2017
|Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects|
TR Johnson, W Tan, L Goulet, EB Smith, S Yamazaki, GS Walker, ...
Xenobiotica 45 (1), 45-59, 2015
|Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects|
J Andrews, D Honeybourne, G Jevons, M Boyce, R Wise, A Bello, ...
Journal of Antimicrobial Chemotherapy 51 (3), 727-730, 2003
|Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma|
L Gibiansky, C Passey, A Roy, A Bello, M Gupta
Journal of pharmacokinetics and pharmacodynamics 43 (3), 243-257, 2016
|Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies|
L Liu, A Bello, MJ Dresser, D Heald, SF Komjathy, E O'Mara, M Rogge, ...
The Journal of Clinical Pharmacology 56 (2), 143-151, 2016
|Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone|
MG Jannuzzo, E Di Salle, R Spinelli, N Pirotta, P Buchan, A Bello
Breast cancer research and treatment 113 (3), 491, 2009
|Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects|
H Xu, M O'Gorman, T Boutros, N Brega, C Kantaridis, W Tan, A Bello
The Journal of Clinical Pharmacology 55 (1), 104-113, 2015
|Effect of a High‐Fat Meal on the Pharmacokinetics of the Des‐F (6)‐Quinolone BMS‐284756|
DA Gajjar, SC Sukoneck, A Bello, Z Ge, L Christopher, DM Grasela
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22 (2 …, 2002
|The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects|
H Xu, M O’Gorman, W Tan, N Brega, A Bello
European journal of clinical pharmacology 71 (12), 1441-1449, 2015